MVC-2G Optimising a Deployable High Efficacy Multi-Stage Vaccine for Plasmodium falciparum Malaria: 2nd Generation Malaria Vaccine Consortium
- Coordinator
- The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
- Runs
- 8 September 2025 to 7 September 2030
- Status
- Running
- EU funding
- €15.0m
- Total cost
- €15.0m
- Partners
- 9 organisations in 8 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101190695
What the project is doing
In the project's own words, from its summary on CORDIS.
The 2nd Generation Malaria Vaccine Consortium (MVC-2G) will build on the programmatic use of the first-generation Plasmodium falciparum vaccine, R21 with Matrix-M™, and accelerate the clinical development of the leading second-generation multi-stage P. falciparum malaria vaccine comprising R21 and two novel blood-stage components, RH5.1 and R78C, all formulated in Matrix-M™. It will achieve this through a multi-disciplinary workplan, underpinned by international cooperation, that will accelerate the future achievement of the United Nations’ Sustainable Development Goal 3 (SDG3) in sub-Saharan African countries.
Its specific objectives are to: 1. Demonstrate safety and superior efficacy against clinical malaria (over R21/MM alone) of the leading second-generation multi-stage vaccine candidate R21+RH5.1+R78C/MM in a Phase 2b trial in 5-17 month old African infants, in a seasonal setting; 2. In parallel, undertake Phase 1b assessment of the second-generation multi-stage vaccine in African infants to define a 3 or 4 dose delivery schedule that is better aligned with EPI and end-user community expectations, aiming for lower cost of goods and to facilitate improved future uptake of a second-generation product; 3.
Demonstrate safety and superior efficacy of the multi-stage vaccine (over R21/MM alone) delivered in an optimised age-based schedule in a multi-site Phase 2b trial in African infants in seasonal and perennial settings; 4. Generate evidence to support use of the multi-stage vaccine in future malaria elimination campaigns by assessment of i) efficacy in adults by CHMI, and ii) safety and immunogenicity in older children; 5.
Support the next-generation of early-career African scientists, across all partners in the Consortium, by growing a South-South network to facilitate hands on clinical and laboratory training; and 6. Undertake early engagement with regulators in partner countries to facilitate translation and future registration of this multi-stage vaccine.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Coordinator |
| Centre National De Recherche Scientifique Et Technologique*institut De Recherche En Sciences De La Sante | Ouagadougou | Burkina Faso | Participant |
| European Vaccine Initiative eV | Heidelberg | Germany | Participant |
| Expres2ion Biotechnologies Aps | Horsholm | Denmark | Participant |
| Centre for Malaria and Other Tropical Diseases Care, Ilorin | Ilorin | NG | Participant |
| University of Sierra Leone | Freetown | SL | Participant |
| Institut Pasteur De Dakar | Dakar | SN | Participant |
| The Registered Trustees of the Ifakara Health Institute | Dar Es Salaam | TZ | Participant |
| London School of Hygiene and Tropical Medicine Royal Charter | London | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI